Melanoma Clinical Trial

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Summary

Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) inhibitor mAb Ipilimumab will be safe and feasible and will show preliminary evidence of anti-tumor efficacy and survival in comparison to historical results following treatment with either agent alone.

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

Metastatic melanoma with activating V600 BRAF mutation
Measurable Tumor
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

Exclusion Criteria:

Autoimmune disease
Active Brain Metastasis (must be stable after radiation for at least one month)
Prior therapy with immune stimulating agents

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT01400451

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

University Of California Los Angeles
Los Angeles California, 90095, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Dana Farber Cancer Inst
Boston Massachusetts, 02215, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT01400451

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider